{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:48:50Z","timestamp":1747158530807,"version":"3.40.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cpt.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:13:42Z","timestamp":1717892022000},"page":"285-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence rate and risk factors of second primary neoplasms among older patients with hematological malignancies: Insights from a Chinese single-center experience (1997\u20132021)"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3002-8739","authenticated-orcid":false,"given":"Yadi","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9710-7786","authenticated-orcid":false,"given":"Bing","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-4210","authenticated-orcid":false,"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-2278","authenticated-orcid":false,"given":"Xuechun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2024.06.001_bib1","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/cam4.2107","article-title":"Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients","volume":"8","author":"Mora","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpt.2024.06.001_bib2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in Hodgkin lymphoma survivors and influence of family history","volume":"35","author":"Sud","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpt.2024.06.001_bib3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.clml.2018.05.021","article-title":"Trends in the risks of secondary cancers in patients with Hodgkin lymphoma","volume":"18","author":"Kumar","year":"2018","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.cpt.2024.06.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.cpt.2024.06.001_bib5","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2024.06.001_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clml.2021.08.002","article-title":"Characterization of second primary malignancies in mucosa-associated lymphoid tissue lymphomas: a SEER database interrogation","volume":"22","author":"Timilsina","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.cpt.2024.06.001_bib7","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s00277-021-04647-0","article-title":"Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies","volume":"100","author":"Sekhri","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cpt.2024.06.001_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/hon.2923","article-title":"Secondary primary malignancies in patients with multiple myeloma: a single institution experience","volume":"39","author":"Fei","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.cpt.2024.06.001_bib9","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpt.2024.06.001_bib10","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/cam4.1461","article-title":"Incidence and survival of hematological cancers among adults ages \u226575 years","volume":"7","author":"Krok-Schoen","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpt.2024.06.001_bib11","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/bcj.2011.39","article-title":"Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms","volume":"1","author":"Rice","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpt.2024.06.001_bib12","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstrom macroglobulinemia: an analysis of the SEER database","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.06.001_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.2010.08538.x","article-title":"Higher risk of primary cancers after polycythaemia vera and vice versa","volume":"153","author":"Fallah","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpt.2024.06.001_bib14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.06.001_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jgo.2020.07.007","article-title":"Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: a population-based analysis","volume":"12","author":"Giri","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.cpt.2024.06.001_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"10.1016\/j.cpt.2024.06.001_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-022-00640-6","article-title":"Increased mortality risk in multiple-myeloma\u00a0patients with subsequent malignancies: a population-based study in The Netherlands","volume":"12","author":"Brink","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpt.2024.06.001_bib18","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large registry analysis to accurately define\u00a0second malignancy rates and risks in a well-characterized cohort of 744\u00a0consecutive multiple myeloma patients followed-up for 25 years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.cpt.2024.06.001_bib19","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.cpt.2024.06.001_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/cncr.32513","article-title":"Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis","volume":"126","author":"Major","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.06.001_bib21","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00432-020-03500-7","article-title":"Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation","volume":"147","author":"Nomura","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cpt.2024.06.001_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12185-018-2538-8","article-title":"Risk of secondary primary malignancies\u00a0in\u00a0multiple myeloma patients with or without autologous stem cell transplantation","volume":"109","author":"Yamasaki","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cpt.2024.06.001_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.06.001_bib24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-term cause-specific mortality in Hodgkin lymphoma patients","volume":"113","author":"de Vries","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cpt.2024.06.001_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2257.1994.tb00414.x","article-title":"Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"16","author":"Tienhaara","year":"1994","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.cpt.2024.06.001_bib26","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2020009871","article-title":"Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia","volume":"138","author":"Duault","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2024.06.001_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.cpt.2024.06.001_bib28","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cpt.2024.06.001_bib29","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.cpt.2024.06.001_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fimmu.2018.00267","article-title":"Acquired natural killer cell dysfunction in the tumor\u00a0microenvironment of classic Hodgkin lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpt.2024.06.001_bib31","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer\u00a0and\u00a0in vivo expansion of human haploidentical NK cells in patients with\u00a0cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2024.06.001_bib32","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.cpt.2024.06.001_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOH.0b013e3283590395","article-title":"Natural killer cell alloreactivity 10 years later","volume":"19","author":"Velardi","year":"2012","journal-title":"Curr Opin Hematol"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T18:55:36Z","timestamp":1726944936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713224000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2949713224000429"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2024.06.001","relation":{},"ISSN":["2949-7132"],"issn-type":[{"type":"print","value":"2949-7132"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence rate and risk factors of second primary neoplasms among older patients with hematological malignancies: Insights from a Chinese single-center experience (1997\u20132021)","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}